It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The aetiology of adolescent idiopathic scoliosis (AIS) has been linked to many factors, such as asymmetric growth, neuromuscular condition, bone strength and genetic background. Recently, epigenetic factors have been proposed as contributors of AIS physiopathology, but information about the molecular mechanisms and pathways involved is scarce. Regarding epigenetic factors, microRNAs (miRNAs) are molecules that contribute to gene expression modulation by regulating important cellular pathways. We herein used Next-Generation Sequencing to discover a series of circulating miRNAs detected in the blood samples of AIS patients, which yielded a unique miRNA biomarker signature that diagnoses AIS with high sensitivity and specificity. We propose that these miRNAs participate in the epigenetic control of signalling pathways by regulating osteoblast and osteoclast differentiation, thus modulating the genetic background of AIS patients. Our study yielded two relevant results: 1) evidence for the deregulated miRNAs that participate in osteoblast/osteoclast differentiation mechanisms in AIS; 2) this miRNA-signature can be potentially used as a clinical tool for molecular AIS diagnosis. Using miRNAs as biomarkers for AIS diagnostics is especially relevant since miRNAs can serve for early diagnoses and for evaluating the positive effects of applied therapies to therefore reduce the need of high-risk surgical interventions.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Rubio-Belmar, Pedro Antonio 2 ; Peiró-Chova, Lorena 3 ; Hervás, David 4
; González-Rodríguez, Daymé 3 ; José Santiago Ibañez-Cabellos 5 ; Bas-Hermida, Paloma 2 ; Mena-Mollá, Salvador 6 ; García-López, Eva María 5 ; Pallardó, Federico V 1 ; Bas, Teresa 2 1 Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Valencia, Spain; Instituto de Investigación Sanitaria INCLIVA, Valencia, Spain; Dept. Physiology. Faculty of Medicine and Dentistry, University of Valencia, Valencia, Spain
2 Instituto de Investigación Sanitaria IISLAFE, Valencia, Spain; Unidad de Raquis. Hospital Universitari i Politècnic La Fe, Valencia, Spain
3 Instituto de Investigación Sanitaria INCLIVA, Valencia, Spain
4 Unidad de Bioestadística, Instituto de Investigación Sanitaria IISLAFE, Valencia, Spain
5 Instituto de Investigación Sanitaria INCLIVA, Valencia, Spain; Dept. Physiology. Faculty of Medicine and Dentistry, University of Valencia, Valencia, Spain
6 Dept. Physiology. Faculty of Medicine and Dentistry, University of Valencia, Valencia, Spain




